Drug Trial Radar · NCT07040319
Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 25, 2026
Primary completion
Mar 3, 2028
Study completion Mar 3, 2028
Sponsor
- Sponsor type
- NIH
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH); AbbVie
- First posted
- Jun 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 16 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, multi-site, open-label, single arm study to describe the pharmacokinetics (PK) and safety of glecaprevir/pibrentasvir (GLE/PIB) initiated during pregnancy in women with hepatitis C virus (HCV) infection (acute or chronic) with or without HIV and to evaluate safety for their infants through 10 weeks postpartum.
Conditions
- Hepatitis C
Interventions
Glecaprevir/pibrentasvirDrug
100 mg glecaprevir and 40 mg pibrentasvir for a total daily dose of glecaprevir 300 mg/pibrentasvir 120 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric mean AUC0-24hTime frame: At weeks 3 & 6
- Geometric mean CmaxTime frame: At weeks 3 & 6
- Geometric mean C24hTime frame: At weeks 3 & 6
- Percentage of pregnant/ postpartum participants who experience a grade 3 or higher adverse event assessed as related to study drugTime frame: Initiation of treatment to a) completion of treatment and b) latter of 10 weeks post-partum or 20 weeks post treatment initiation
- Percentage of pregnant participants who experience a serious adverse event assessed as related to study drugTime frame: Initiation of treatment to a) completion of treatment and b) latter of 10 weeks post-partum or 20 weeks post treatment initiation
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
USC LA
Los Angeles, California · Recruiting
David Geffen School of Medicine at UCLA
Los Angeles, California · Not yet recruiting
University of Colorado Denver
Aurora, Colorado · Recruiting
Univ. of Florida Jacksonville
Jacksonville, Florida · Recruiting
Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Johns Hopkins University Baltimore
Baltimore, Maryland · Recruiting
SUNY Stony Brook
Stony Brook, New York · Recruiting
Bronx-Lebanon Hospital Center
The Bronx, New York · Recruiting
Jacobi Medical Center
The Bronx, New York · Not yet recruiting
Baylor College of Medicine//Texas Children's Hospital
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.